V originále
Recent reports suggested that homocystinuria due to cystathionine beta-synthase (CBS) deficiency is a more common inborn error of metabolism than originally thought. In this study we compared the prevalence of homocystinuric alleles ascertained by two different approaches. First, the incidence of homocystinuria estimated by selective biochemical screening in the Czech and Slovak Republics was 1:349,000 (95% CI 1:208,000-1:641,000). The two most common pathogenic mutant alleles found subsequently in these patients, IVS11-2A>C and c.833T>C, had a calculated population prevalence of 0.00042 (95% CI 0.00031-0.00055) and 0.00018 (95% CI 0.00013-0.00023), respectively. Second, to examine the possible negative detection bias of mildly affected patients we determined the prevalence of these two pathogenic mutations in a sample of 1284 unselected newborns. Indeed, the observed prevalence of the c.833T>C allele (0.00195, 95% CI 0.00063-0.00454) was 11x higher than in the previous group suggesting that many homozygotes for the c.833T>C had not been diagnosed by selective biochemical screening. The IVS11-2A>C allele was not detected among 2,568 newborn CBS alleles. The estimated incidence of homocystinuria of 1:83,000, calculated in a combined model, suggests that selective biochemical screening may ascertain only 25% of all homocystinuric patients. In conclusion, homocystinuria in Central Europe may be sufficiently common to consider sensitive newborn screening programs for this disease.
Česky
V této studii byla porovnána prevalence alel spojených s homocystinurií dvěma přístupy. Incidence homocystinurie na základě výsledků biochemického screeningu je 1:349000. Dvě nejběžnější alely genu pro cystathionin beta-syntázu (IVS11-2A>C a c.833T>C)detekované u těchto pacientů, mají kalkulovanou populační frekvenci 0.00042, resp. 0,00018. Výskyt obou alel byl stanoven v souboru 1284 neselektovaných novorozenců (0.0, resp. 0.00195) a z kombinovaného modelu byla vypočtena frekvence onemocnění v české populaci 1:83000. To znamená, že biochemický screening zachytí pouze 25 % pacientů s homocystinurií.